BioSpace News Archive

Locanabio, Inc., an RNA-targeting gene therapy company focused on developing life-changing therapies for patients with severe neurodegenerative, neuromuscular and retinal diseases, announced that new data from its preclinical research will be highlighted in oral and poster presentations at the 24th Annual American Society of Gene and Cell Therapy Meeting, taking place virtually from May 11-14, 2021.

Paul J. Diaz, president and CEO of Myriad Genetics, Inc., a leader in genetic testing and precision medicine, will discuss the company’s transformation plan and growth initiatives during a fireside chat at the Bank of America Securities 2021 Virtual Health Care Conference at 2:45 p.m. EDT on May 12, 2021.

Data from the ALLO-501 ALPHA Study and ALLO-501A ALPHA2 Study to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced financial results for the first quarter ended March 31, 2021.

Fiscal fourth quarter 2021 revenue of $59.2 million, a 33% increase compared to fiscal fourth quarter 2020 revenue of $44.4 million

Applied Genetic Technologies Corporation announced that it plans to release 12-month data for Groups 5 and 6 evaluating durability of effect and continued safety at higher doses and 24-month data evaluating durability from a subset of Group 4 patients for its Phase 1/2 clinical trial in patients with X-linked Retinitis Pigmentosa on Thursday, May 6, 2021.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, provided a corporate update, and reported financial results for the three months ended March 31, 2021.

Newly released PK/PD data from prior study in PGHD support endogenous LUM-201 MOA and use of Predictive Enrichment Markers (PEMs) to identify patients likely to respond to LUM-201

Nicox SA, an international ophthalmology company, announced the signature of an exclusive license agreement with Laboratorios Grin, a wholly-owned subsidiary of Lupin Limited, for the registration and commercialization of ZERVIATETM, 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in Mexico.

Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development announced the signing of a Definitive Agreement with DanCann Pharma A/S for the exclusive distribution of Reduvo™ Adversa®, QIXLEEF™ and ENJOUCA™ in Denmark, Norway, Sweden, Finland, and Germany.